ABVC BioPharma

If any candidate is approved in narrow indications, list pricing could be meaningful relative to manufacturing cost, creating theoretical pricing power.

However, there is no approved asset, payer value propositions are unproven, and botanic‑based mechanisms may face formulary skepticism. 2025 revenue was zero and no commercial pricing exists, so realized pricing power is currently none. Score reflects only contingent, future potential if pivotal trials succeed.